Human disease
vitelliform macular dystrophy 2
Mondo defines it as: “Best vitelliform macular dystrophy (BVMD) is a genetic macular dystrophy characterized by loss of central visual acuity, metamorphopsia and a decrease in the Arden ratio secondary to an egg yolk-like lesion located in the foveal or parafoveal region.”
4 disease groups in OMIA reach this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 1444 | Multifocal retinopathy 1 | OMIA's OMIM numbers | 1 | Target evidence |
58.6
|
| 1553 | Multifocal retinopathy 2 | OMIA's OMIM numbers | 1 | Target evidence |
58.6
|
| 1554 | Multifocal retinopathy 3 | OMIA's OMIM numbers | 1 | Target evidence |
58.6
|
| 2976 | Macular dystrophy, BEST1-related | OMIA's OMIM numbers | 1 | Target evidence |
58.6
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
| Human gene | Score | Evidence |
|---|---|---|
| BEST1 | 0.85 | 544 |
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
No drug has been tested for this disease.